Safety and Efficacy of Low‐Volume Plasma Exchange in the Management of <scp>COVID‐19‐</scp> Associated Guillain‐Barré Syndrome: A Case Report

Guillain-Barré syndrome (GBS) is a rare but severe neurological complication associated with COVID-19, often leading to significant morbidity. Plasma exchange (PE) is a cornerstone treatment for GBS, but its widespread use can be limited by hemodynamic instability and logistical challenges. Low-volume plasma exchange (LVPE) has emerged as a safer alternative, providing comparable therapeutic benefits while minimizing procedural risks. This case report presents a patient with COVID-19-associated GBS who underwent LVPE using a modified exchange protocol with a nanomembrane filtration system. This approach allowed for controlled plasma removal and minimized cardiovascular strain. Neurological rehabilitation was initiated simultaneously with LVPE, contributing to the patient's gradual recovery. Following the procedure and rehabilitation, the patient showed significant neurological improvement without notable adverse effects. These findings suggest that LVPE, in combination with rehabilitation, may be an effective therapeutic strategy, particularly in resource-limited or high-risk clinical settings. The results highlight the potential of LVPE as an adjunctive treatment for inflammatory neuropathies, especially in COVID-19-related cases, and advocate for further investigation into its safety and efficacy.